# COVID-19 Vaccine Boosters in Patients With CKD

> **NCT05022329** · PHASE2,PHASE3 · TERMINATED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 273 (actual)

## Conditions studied

- Chronic Kidney Diseases
- COVID-19

## Interventions

- **BIOLOGICAL:** Pfizer-BioNTech COVID-19 Vaccine
- **BIOLOGICAL:** MODERNA SARS-CoV-2 Vaccine

## Key facts

- **NCT ID:** NCT05022329
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-30
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-11-15
- **Target enrollment:** 273 (ACTUAL)
- **Why stopped:** Trial participants became eligible to receive their 4th dose of the COVID-19 vaccine vaccine thus data collected from the 12 month follow-up after 3rd dose vaccine, as per current protocol, would not not be relevant to the study outcomes.
- **Last updated:** 2025-02-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022329, "COVID-19 Vaccine Boosters in Patients With CKD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05022329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*